Welcome to Our Family
MPP has formally opened its doors in 2016. The facility is brand new, functional and designed for development of Injectable Drug Products meeting cGMP standards. Our 35,000sq ft site consists of 5 laboratories equipped with qualified and validated instrumentation and includes over 12,000 sq ft of available space for future expansion for sterile manufacturing.
MPP Group has been launched as a logical continuation of services and products positioned “closer to the patient”, i.e., we focus on development and formulations of injectable drug products, both for our own and third party products.
We have state-of-the-art instrumentation both in the analytical and formulation departments and our goal is to be able to perform any analytical test related to the development of DP.
Our predecessor, Namigen LLC (a partnership with Nathan Barishansky), exposed us to development of injectable drug products. We developed four drug candidates and one of them, Sodium Nitroprusside USP Injection, has been approved and has been on the market since December, 2016.
Finally, I would like to thank all my Friends and Colleagues within the broad pharmaceutical industry for their encouragement and support during the construction and startup period, as well as our customers for their trust in us.
Thank you for visiting our website and we look forward to doing business with you!
Michael W. Major, Ph.D., D.Sc.
President and CEO